Telmisartan may also reduce new onset of LVH ( nonhypertensive patients P < 0.05 ; hypertensive patients P < 0.001 ) in both subgroups , and new onset of microalbuminuria and macroalbuminuria in hypertensive patients ( P < 0.001 and P < 0.01 , respectively ) .